Form 4: Gossamer Bio EVP Awarded Performance Stock Units

Gossamer Bio's EVP of Regulatory Affairs, Caryn Peterson, received 125,000 performance stock units tied to seralutinib NDA approval or a change in control.

Summary

• Caryn Peterson, Executive Vice President of Regulatory Affairs at Gossamer Bio, Inc. (GOSS), was granted 125,000 shares of common stock.
• This grant, dated October 1, 2025, represents a performance stock unit (PSU) award.
• The PSUs will vest in full upon the earlier of the approval of a new drug application (NDA) for seralutinib or a change in control of the company.
• Vesting is contingent on these events occurring on or prior to the fourth anniversary of the grant date and Ms. Peterson's continuous service to the Issuer.
• Following this transaction, Ms. Peterson beneficially owns a total of 174,833 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of performance stock units to a key executive, tied to a significant drug approval milestone (seralutinib NDA), indicates a strategic alignment of incentives and confidence in the drug's potential. While the vesting is conditional, it reflects a positive long-term outlook for a critical pipeline asset.

Positives

• The grant of performance stock units aligns executive incentives directly with a critical corporate milestone: the New Drug Application (NDA) approval for seralutinib.
• The award structure incentivizes the successful development and regulatory achievement of seralutinib, a key pipeline asset for Gossamer Bio.

Negatives

• The award has no immediate cash value, as it is a performance-based grant with future vesting conditions.
• Vesting is contingent on specific future events (NDA approval or change in control), introducing uncertainty regarding the realization of the award's value.

Risks

• The vesting of the performance stock units is subject to the successful approval of a new drug application for seralutinib, which carries inherent regulatory and clinical development risks.
• Vesting is also dependent on Caryn Peterson's continuous service to Gossamer Bio, Inc., posing a risk if her employment terminates prior to vesting.

Future Outlook

The vesting conditions for the performance stock units highlight the company's strategic focus on achieving New Drug Application (NDA) approval for seralutinib and acknowledge the potential for a future change in control within the next four years.

Management Comments

• The company is strategically aligning executive compensation with critical regulatory milestones, specifically the potential New Drug Application approval for seralutinib.

Industry Context

The grant of performance-based equity awards tied to specific drug development milestones is a common practice in the biotechnology and pharmaceutical industries to incentivize key executives and align their interests with long-term company success and shareholder value creation.

Comparison to Industry Standards

• Performance Stock Units (PSUs) tied to specific drug development milestones, such as New Drug Application (NDA) approval, are a common executive compensation practice in the biotechnology and pharmaceutical industries.
• This structure is comparable to incentive plans at companies like Biogen (BIIB) or Gilead Sciences (GILD), where executive bonuses and equity awards are often linked to clinical trial success, regulatory submissions, and market approvals for key pipeline assets.
• The inclusion of a 'change in control' clause is also standard in executive compensation agreements across various industries, providing a retention incentive and protecting executive interests during M&A activities.

Related Party Transactions

• Grant of 125,000 performance stock units to Caryn Peterson, an executive officer (EVP, Regulatory Affairs), as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential long-term value creation if seralutinib achieves NDA approval, as executive incentives are aligned with this key milestone.
• Employees: May signal confidence in the company's pipeline and strategic direction, potentially boosting morale.

Next Steps

• Continued development and regulatory efforts for seralutinib towards New Drug Application (NDA) approval.
• Caryn Peterson's continuous service to Gossamer Bio, Inc. to meet vesting conditions.

Key Dates

Recommendation

The grant of performance stock units to a key executive, contingent on the approval of a significant drug candidate (seralutinib NDA), indicates strong internal alignment and confidence in the company's pipeline. While this is a positive signal for long-term value creation, it is a single event and does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor further developments regarding seralutinib and overall company performance.

Keywords

Gossamer Bio, GOSS, Caryn Peterson, EVP Regulatory Affairs, Performance Stock Units, PSU, Seralutinib, NDA approval, Change in Control, Executive Compensation, SEC Form 4, Insider Transaction